US CNS Disorders Drug Pipeline Insight 2014

Publish Date:- Aug-2014       No Of Pages (1700)

Electronic Access - Single User License $2400 Buy Now
CD-ROM Mail Delivery $2800Buy Now
Hard Copy Mail Delivery $3600 Buy Now
Electronic Access - Multi-User License $4800 Buy Now


The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. In US, the numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the largest therapeutic categories and also one of the fastest growing. US account for more than 55% of the global CNS Disorders drugs market.

Within the CNS market, the biggest therapeutic area is the market for anti-psychotics, followed by anti-depressive and mood stab markets. Anti-epileptic and anti-Alzheimer’s markets come next while other classes of drugs have a marginal share. Antipsychotics have a market share of nearly 30% while antidepressants corner about 25% of the market. Anti convulsants have about 17% of the market share while drugs used in Alzheimer's Disease form about 9% of the market, with ADHD and narcolepsy drugs medications have about 7% market share. The other classes of drugs have market shares of less than 5% each.

New technology including advancements in stem cell therapy and of nanotechnology is expected to drive the growth of the CNS market. Nanotechnology in the form of the nanomaterials for wound care, drug delivery and immunomodulation is specifically seen as a positive influence on CNS therapy that is expected to open growth opportunities. While each of these therapeutic subcategories are served by established treatments there are certain markets segments with significant unmet medical needs still remain, indicating potential in these areas. There are newer treatment methodologies under development such as that using stem cell therapy and of nanotechnology that seek to address these opportunities.

The rapid advances in the R&D segment, many novel drugs are currently available for the treatment of CNS disorders. Industry related to CNS drug delivery system has also got a boost due to rapid advancement of CNS disorders market. Given the magnitude of number of patients and demand for better drugs is going to push pharmaceutical companies for significant investments. Changing life-style is one the main contributor of CNS disorders in US. Increased longevity and ageing population along with launch of novel drugs will drive the growth of CNS disease market in future.

US CNS Disorders Drug Pipeline Insight 2014” Report Highlight:

• Market Overview & Incidence by Disease
• CNS Disorder Market Dynamics
• CNS Disorder Pipeline by disease, Phase & Company
• CNS Disorder Pipeline: 1083 Drugs in Pipeline
• Majority CNS Drugs in Preclinical Phase: 396 Drugs
• Majority CNS Drugs for Neurodegenerative Disorders: 228 Drugs in Pipeline
• CNS Disorder Market Drugs: 109 Drugs
• Majority CNS Drugs Marketed for Epilepsy: 24 Drugs


The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. In US, the numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the largest therapeutic categories and also one of the fastest growing. US account for more than 55% of the global CNS Disorders drugs market.

Within the CNS market, the biggest therapeutic area is the market for anti-psychotics, followed by anti-depressive and mood stab markets. Anti-epileptic and anti-Alzheimer’s markets come next while other classes of drugs have a marginal share. Antipsychotics have a market share of nearly 30% while antidepressants corner about 25% of the market. Anti convulsants have about 17% of the market share while drugs used in Alzheimer's Disease form about 9% of the market, with ADHD and narcolepsy drugs medications have about 7% market share. The other classes of drugs have market shares of less than 5% each.

New technology including advancements in stem cell therapy and of nanotechnology is expected to drive the growth of the CNS market. Nanotechnology in the form of the nanomaterials for wound care, drug delivery and immunomodulation is specifically seen as a positive influence on CNS therapy that is expected to open growth opportunities. While each of these therapeutic subcategories are served by established treatments there are certain markets segments with significant unmet medical needs still remain, indicating potential in these areas. There are newer treatment methodologies under development such as that using stem cell therapy and of nanotechnology that seek to address these opportunities.

The rapid advances in the R&D segment, many novel drugs are currently available for the treatment of CNS disorders. Industry related to CNS drug delivery system has also got a boost due to rapid advancement of CNS disorders market. Given the magnitude of number of patients and demand for better drugs is going to push pharmaceutical companies for significant investments. Changing life-style is one the main contributor of CNS disorders in US. Increased longevity and ageing population along with launch of novel drugs will drive the growth of CNS disease market in future.

US CNS Disorders Drug Pipeline Insight 2014” Report Highlight:

• Market Overview & Incidence by Disease
• CNS Disorder Market Dynamics
• CNS Disorder Pipeline by disease, Phase & Company
• CNS Disorder Pipeline: 1083 Drugs in Pipeline
• Majority CNS Drugs in Preclinical Phase: 396 Drugs
• Majority CNS Drugs for Neurodegenerative Disorders: 228 Drugs in Pipeline
• CNS Disorder Market Drugs: 109 Drugs
• Majority CNS Drugs Marketed for Epilepsy: 24 Drugs

1. Introduction to Central Nervous System (CNS) Disorder

 

2. US Central Nervous System (CNS) Disorder Market Overview

  2.1 Market Overview

  2.2 Clinical Pipeline Insight

 

3. US Central Nervous System (CNS) Disorder Incidence by Disease

  3.1 Alzheimer's Disease

  3.2 Multiple Sclerosis

  3.3 Epilepsy

  3.4 Parkinson Disease

  3.5 Migraine

  3.6 Huntington's disease

  3.7 Schizophrenia

  3.8 Anxiety

  3.9 Insomnia

  3.10 Bipolar Disorder

  3.11 ADHD

 

4. US Central Nervous System (CNS) Disorder Market Dynamics

  4.1 Favorable Market Parameters

  4.2 Market Challenges

  4.3 Future Growth Opportunity

 

5. US Multiple CNS Disorder Drug Pipeline by Phase & Company

  5.1 Clinical Pipeline Insight by Phase & Company

  5.2 Marketed Drugs Clinical Profile

 

6. US Alzheimer's Disease Drug Pipeline by Phase & Company

  6.1 Clinical Pipeline Insight by Phase & Company

  6.2 Marketed Drug Clinical Profile

 

7. US Multiple Sclerosis Drug Pipeline by Phase & Company

  7.1 Clinical Pipeline Insight by Phase & Company

  7.2 Marketed Drug Clinical Profile

 

8. US Parkinson's Disease Drug Pipeline by Phase & Company

  8.1 Clinical Pipeline Insight by Phase & Company

  8.2 Marketed Drug Clinical Profile

 

9. US CNS Disorder/Neurodegenerative Disorders Drug Pipeline by Phase & Company

  9.1 Clinical Pipeline Insight by Phase & Company

  9.2 Marketed Drug Clinical Profile

 

10. US Epilepsy Drug Pipeline by Phase & Company

  10.1 Clinical Pipeline Insight by Phase & Company

  10.2 Marketed Drug Clinical Profile

 

11. US Migraine Drug Pipeline by Phase & Company

  11.1 Clinical Pipeline Insight by Phase & Company

  11.2 Marketed Drug Clinical Profile

 

12. US Huntington's Disease Drug Pipeline by Phase & Company

  12.1 Clinical Pipeline Insight by Phase & Company

  12.2 Marketed Drug Clinical Profile

 

13. US Neuropathic Pain Clinical Pipeline by Phase & Company

  13.1 Clinical Pipeline Insight by Phase & Company

  13.2 Marketed Drug Clinical Profile

 

14. US Schizophrenia Clinical Trial Insight by Phase & Company

  14.1 Clinical Pipeline Insight by Phase & Company

  14.2 Marketed Drug Clinical Profile

 

15. US Sleep Disorders Drug Pipeline by Phase & Company

  15.1 Clinical Pipeline Insight by Phase & Company

  15.2 Marketed Drug Clinical Profile

 

16. Competitive Landscape

  16.1 Alkermes

  16.2 Allergan

  16.3 AstraZeneca

  16.4 Biogen Idec

  16.5 Bristol-Myers Squibb

  16.6 Eli Lilly

  16.7 GlaxoSmithKline

  16.8 Merck

  16.9 Novartis

  16.10 Pfizer

  16.11 Roche

  16.12 Sanofi

  16.13 Sunovion Pharmaceuticals

  16.14 Teva Pharmaceutical


Figure 2-1: US – CNS Disorders Drugs Clinical Pipeline by Phase (%), 2014

Figure 2-2: US – CNS Disorders Drugs Clinical Pipeline by Phase (Number), 2014

Figure 2-3: US – CNS Disorder Drugs Clinical Pipeline by Disease (%), 2014

Figure 2-4: US – CNS Disorder Drugs Clinical Pipeline by Disease (Number), 2014

                                                       

Figure 2-5: US – CNS Disorder Drugs in Research Phase by Disease (%), 2014

Figure 2-6: US – CNS Disorder Drugs in Research Phase by Disease (Number), 2014

Figure 2-7: US – CNS Disorder Drugs in Preclinical Phase by Disease (%), 2014

Figure 2-8: US – CNS Disorder Drugs in Preclinical Phase by Disease (Number), 2014

Figure 2-9: US – CNS Disorder Drugs in Clinical Phase by Disease (%), 2014

Figure 2-10: US – CNS Disorder Drugs in Clinical Phase by Disease (Number), 2014

Figure 2-11: US – CNS Disorder Drugs in Phase-0 by Disease (%), 2014

Figure 2-12: US – CNS Disorder Drugs in Phase-0 by Disease (Number), 2014

Figure 2-13: US – CNS Disorder Drugs in Phase-I by Disease (%), 2014

Figure 2-14: US – CNS Disorder Drugs in Phase-I by Disease (Number), 2014

Figure 2-15: US – CNS Disorder Drugs in Phase-I/II by Disease (%), 2014

Figure 2-16: US – CNS Disorder Drugs in Phase-I/II by Disease (Number), 2014

Figure 2-17: US – CNS Disorder Drugs in Phase-II by Disease (%), 2014

Figure 2-18: US – CNS Disorder Drugs in Phase-II by Disease (Number), 2014

Figure 2-19: US – CNS Disorder Drugs in Phase-II/III by Disease (%), 2014

Figure 2-20: US – CNS Disorder Drugs in Phase-II/III by Disease (Number), 2014

Figure 2-21: US – CNS Disorder Drugs in Phase-III by Disease (%), 2014

Figure 2-22: US – CNS Disorder Drugs in Phase-III by Disease (Number), 2014

Figure 2-23: US – CNS Disorder Drugs in Preregistration Phase by Disease (%), 2014

Figure 2-24: US – CNS Disorder Drugs in Preregistration Phase by Disease (Number), 2014

Figure 2-25: US – CNS Disorder Drugs in Registration Phase by Disease (%), 2014

Figure 2-26: US – CNS Disorder Drugs in Registration Phase by Disease (Number), 2014

 

Figure 2-27: US – Marketed CNS Disorder Drugs by Disease (%), 2014

Figure 2-28: US – Marketed CNS Disorder Drugs by Disease (Number), 2014

 

Figure 2-29: US – Alzheimer s Disease Drugs Clinical Pipeline by Phase (%), 2014

Figure 2-30: US – Alzheimer s Disease Drugs Clinical Pipeline by Phase (Number), 2014

Figure 2-31: US – Multiple Sclerosis Drugs Clinical Pipeline by Phase (%), 2014

Figure 2-32: US – Multiple Sclerosis Drugs Clinical Pipeline by Phase (Number), 2014

 

Figure 2-33: US – Parkinson s Disease Drugs Clinical Pipeline by Phase (%), 2014

Figure 2-34: US – Parkinson s Disease Drugs Clinical Pipeline by Phase (Number), 2014

 

Figure 2-35: US – Neurodegenerative Disorders Drugs Clinical Pipeline by Phase (%), 2014

Figure 2-36: US – Neurodegenerative Disorders Drugs Clinical Pipeline by Phase (Number), 2014

Figure 2-37: US – Epilepsy Drugs Clinical Pipeline by Phase (%), 2014

Figure 2-38: US – Epilepsy Drugs Clinical Pipeline by Phase (Number), 2014

 

Figure 2-39: US – Migraine Drugs Clinical Pipeline by Phase (%), 2014

Figure 2-40: US – Migraine Drugs Clinical Pipeline by Phase (Number), 2014

 

Figure 2-41: US – Huntington s Disease Drugs Clinical Pipeline by Phase (%), 2014

Figure 2-42: US – Huntington s Disease Drugs Clinical Pipeline by Phase (Number), 2014

 

Figure 2-43: US – Neuropathic Pain Drugs Clinical Pipeline by Phase (%), 2014

Figure 2-44: US – Neuropathic Pain Drugs Clinical Pipeline by Phase (Number), 2014

 

Figure 2-45: US – Schizophrenia Drugs Clinical Pipeline by Phase (%), 2014

Figure 2-46: US – Schizophrenia Drugs Clinical Pipeline by Phase (Number), 2014

 

Figure 2-47: US – Sleep Disorders Drugs Clinical Pipeline by Phase (%), 2014

Figure 2-48: US – Sleep Disorders Drugs Clinical Pipeline by Phase (Number), 2014

 

Figure 3-1: US - Alzheimer’s Disease Incidence (Million), 2013-2020

Figure 3-2: US - Multiple Sclerosis Incidence (‘000), 2013-2020

Figure 3-3: US - Epilepsy Incidence (Million), 2013-2020

Figure 3-4: US - Parkinson’s Disease Incidence (Million), 2013-2020

Figure 3-5: US - Migraine Incidence (Million), 2013-2020

Figure 3-6: US - Huntington’s Disease Incidence (‘000), 2013-2020

Figure 3-7: US - Schizophrenia Disease Incidence (Million), 2013-2020

Figure 3-8: US - Anxiety Disorder Incidence (Million), 2013-2020

Figure 3-9: US - Insomnia Incidence (Million), 2013-2020

Figure 3-10: US - Bipolar Disorder Incidence (Million), 2013-2020

Figure 3-11: US - ADHD Incidence (Million), 2013-2020